These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26291590)

  • 1. Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir.
    Srinivas NR
    Am J Ther; 2017; 24(4):e405-e418. PubMed ID: 26291590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.
    Srinivas NR; Syed M
    Drugs R D; 2016 Mar; 16(1):69-79. PubMed ID: 26747454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drug-Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy.
    Srinivas NR
    Am J Ther; 2019; 26(1):e54-e65. PubMed ID: 26808357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of area under the concentration-time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir-ritonavir therapy.
    Srinivas NR
    Am J Health Syst Pharm; 2016 Mar; 73(6):376-85. PubMed ID: 26953282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data.
    Srinivas NR
    Biopharm Drug Dispos; 2015 Dec; 36(9):575-86. PubMed ID: 26224332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited Sampling Strategy for the Prediction of Area Under the Curve (AUC) of Statins: Reliability of a Single Time Point for AUC Prediction for Pravastatin and Simvastatin.
    Srinivas NR
    Drug Res (Stuttg); 2016 Feb; 66(2):82-93. PubMed ID: 26011815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application.
    Srinivas NR; Syed M
    J Pain Palliat Care Pharmacother; 2016; 30(1):13-24. PubMed ID: 26865407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.
    De Wit S; Debier M; De Smet M; McCrea J; Stone J; Carides A; Matthews C; Deutsch P; Clumeck N
    Antimicrob Agents Chemother; 1998 Feb; 42(2):223-7. PubMed ID: 9527763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
    J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting.
    Boffito M; Bonora S; Raiteri R; Reynolds HE; Hoggard PG; Sinicco A; Back DJ; Di Perri G
    Ther Drug Monit; 2002 Aug; 24(4):574-6. PubMed ID: 12142647
    [No Abstract]   [Full Text] [Related]  

  • 11. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.
    Boruchoff SE; Sturgill MG; Grasing KW; Seibold JR; McCrea J; Winchell GA; Kusma SE; Deutsch PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):351-9. PubMed ID: 10801243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
    Srinivas NR
    Drug Dev Ind Pharm; 2016; 42(6):945-57. PubMed ID: 26467209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidence-based therapeutic drug monitoring for indinavir].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):239-46. PubMed ID: 21819808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
    Ferry JJ; Herman BD; Carel BJ; Carlson GF; Batts DH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):252-9. PubMed ID: 9665503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
    Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
    Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
    Collin F; Chêne G; Retout S; Peytavin G; Salmon D; Bouvet E; Raffi F; Garraffo R; Mentré F; Duval X;
    Ther Drug Monit; 2007 Apr; 29(2):164-70. PubMed ID: 17417069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of azithromycin on the pharmacokinetics of indinavir.
    Foulds G; LaBoy-Goral L; Wei GC; Apseloff G
    J Clin Pharmacol; 1999 Aug; 39(8):842-6. PubMed ID: 10434237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models.
    Bhamidipati RK; Syed M; Mullangi R; Srinivas N
    Xenobiotica; 2018 Feb; 48(2):148-156. PubMed ID: 28290233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.